GALNT5 and breast cancer: The majority (~74%) of these genes showed an overall increase in expression following decitabine treatment (Fig. 5c) and included established ER target genes (for example, B4GALT1, MYO3B, SEMA3G) as well as genes associated with good clinical outcome in ER+ breast cancer (for example, SPATA18, SCUBE2, GALNT5, IGFBP4).